Larimar Therapeutics, Inc. (LRMR)
NASDAQ: LRMR · Real-Time Price · USD
3.700
+0.020 (0.54%)
Dec 5, 2025, 4:00 PM EST - Market closed
Larimar Therapeutics Stock Forecast
Stock Price Forecast
According to 7 professional analysts, the 12-month price target for Larimar Therapeutics stock ranges from a low of $7.00 to a high of $26. The average analyst price target of $16.71 forecasts a 351.62% increase in the stock price over the next year.
Price Target: $16.71 (+351.62%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Oct 2, 2025.
Analyst Ratings
The average analyst rating for Larimar Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 3 | 3 | 3 | 3 |
| Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $26 → $21 | Buy | Maintains | $26 → $21 | +467.57% | Oct 2, 2025 |
| Wedbush | Wedbush | Buy Maintains $15 → $11 | Buy | Maintains | $15 → $11 | +197.30% | Sep 30, 2025 |
| Baird | Baird | Buy Maintains $10 → $7 | Buy | Maintains | $10 → $7 | +89.19% | Sep 30, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $18 | Buy | Reiterates | $18 | +386.49% | Aug 19, 2025 |
| JMP Securities | JMP Securities | Buy Maintains $22 → $18 | Buy | Maintains | $22 → $18 | +386.49% | Aug 15, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
2.07M
EPS This Year
-2.00
from -1.32
EPS Next Year
-1.91
from -2.00
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | 17.0M | ||||
| Avg | n/a | 2.1M | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.62 | -1.14 | ||||
| Avg | -2.00 | -1.91 | ||||
| Low | -2.14 | -2.61 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.